survival is 9-12 months in patients with large tumour burdens. 3,4 High-dose chemotherapy without hematopoietic support We report the results of a consecutive series of patients who underwent autologous (auto) (40), allogeneic (allo) results in both responses and durable remissions in some patients with MM refractory to standard therapy but com-(22) or syngeneic transplantation (2) for multiple myeloma (MM) at our centre. Median age at diagnosis was plications of myelosuppression are common. [5][6][7] High-dose therapy with autologous, syngeneic or allogeneic hemato-45.5 (auto) and 43 (allo) years. Most patients had stage 2 (27% auto; 27% allo) or stage 3 (62% auto; 50% allo) poietic support has been employed for almost two decades to achieve durable disease control and cure in patients with disease and 73% demonstrated chemosensitivity prior to transplant. Median time from diagnosis to transplant MM. 8 The source of hematopoietic cells, timing of transplantation and patients who may benefit from high-dose was 18.6 months (auto) and 16.4 months (allo). Standard conditioning regimens were used. Median time to therapy are not yet well defined. Randomized trials addressing some of these issues are underway or have recently neutrophil engraftment was 11 days (7-18) (auto) and 18 days (13-24) (allo) and median time to platelet been reported.
Physicians and patients face a number of dilemmas in engraftment was 11 days (6-60) and 18 days (13-105), respectively. Ninety-day mortality was 5% (auto) and comparing autologous and allogeneic transplants for the treatment of MM. Autologous transplants are available to 27% (allo). Median follow-up was 15 months (6-48) (auto) and 42 months (24-52) (allo). Three-year more patients since age restrictions are less stringent and an HLA-matched donor is not required. They have also been progression-free survival (PFS) was 17 ± 10% (auto) and 22 ± 9% (allo) and 3-year overall survival (OS) was associated with lower procedure-related toxicity 9-11 and are not complicated by GVHD. Allogeneic transplants for MM 74 ± 11% (auto) and 32 ± 10% (allo). Autologous transplantation for MM is a safe procedure with good OS have been associated with significant acute toxicity although this may in part reflect selection of heavily treated although disease progression following transplant is frequent. Allogeneic transplantation has a high procedurepatients with advanced disease. 12,13 However, allogeneic grafts are free of contamination by tumour cells and the related mortality and PFS comparable to autologous transplantation but OS is poor. The early mortality and immunologic benefit of genetic disparity between host myeloma cells and donor cells may be important in mainhigh OS of autologous transplantation in MM compares favourably with both the results of allogeneic transplantaining long-term disease control. Among high-dose therapies, it is not yet evident whether patients benefit more tation and published results of standard therapy in this retrospective analysis.
from autologous or allogeneic transplant. We describe a consecutive series of 64 patients who have Keywords: multiple myeloma; autologous bone marrow transplantation; allogeneic bone marrow transplantation undergone autologous, syngeneic or allogeneic transplantation for MM in Toronto, Canada from 1983 to 1995. Characteristics of the patients referred for transplant, transplant eligibility and supportive care have evolved over the Multiple myeloma (MM) is a fatal B cell neoplasm characyears described in this report. This retrospective series of terised by lytic bone disease, paraproteinemia and bone consecutive patients provides an estimate of acute toxicity, marrow infiltration with malignant plasma cells.
1 Median progression-free survival (PFS) and overall survival (OS) survival is 30-36 months with melphalan and prednisone of patients with MM who have been treated with high-dose but the course of the disease is variable and survival can therapy and transplantation at one centre. range from months to greater than 10 years.
2 Median were contacted when follow-up information for the 6 was greater than 20 × 10 12 /l not due to platelet transfusion. Neutrophil engraftment failure was a neutrophil count months preceding July 1996 was not available in the hospital record for surviving patients. Autologous transplants less than 0.5 × 10 9 /l at day 35 post-transplant. Platelet engraftment failure was a platelet count less than were undertaken between 1992 and 1995 and allogeneic and syngeneic transplants between 1983 and 1995. 50 × 10 12 /l at day 100 and red cell engraftment failure was present if there was an ongoing requirement for red cell Pre-transplant characteristics were recorded for each patient (Table 1) . Extent of disease was staged according transfusion at day 100. Acute and chronic GVHD were graded according to published criteria. 16, 17 Days to first hosto Durie and Salmon.
14 Extensive bone disease was defined as greater than three lytic bone lesions on skeletal survey. pital discharge, PFS and OS were calculated from the day of BM or PBPC infusion (day 0). Patients who died within Response to pre-transplant chemotherapy and transplant were categorized according to SWOG response gradations 15 90 days of transplant were not evaluable for disease progression. Deaths were classified as due to MM, infection as complete remission (CR), near complete remission (N-CR), partial remission (PR), stable disease (SD) or proor other cause, taking into account autopsy findings when available. gression (PG). Chemosensitive disease was defined as a greater than 50% reduction in plasma monoclonal protein or a greater than 90% reduction in urine monoclonal protein
Common supportive care with no evidence of progression of bone disease in response to the chemotherapy regimen immediately preceding transAll patients were nursed in private rooms with protective isolation and received irradiated blood products. CMVplant. Patients without measurable disease or whose only evidence of disease was lytic bone lesions (non-secreting negative recipients of CMV-negative transplants received unfiltered CMV-negative blood products. Since 1987, myeloma) were included in the analysis of overall survival (OS) and progression-free survival (PFS) but not assessed patients received acyclovir for 14-28 days following transplant as herpes simplex virus prophylaxis. Intravenous for response to therapy or chemosensitivity.
Neutrophil engraftment was defined as the first of 2 days immunoglobulins, ganciclovir and anti-fungal agents were not routinely administered following transplant. All patients when the neutrophil count rose above 0.5 × 10 9 /l. Platelet engraftment was the first of 2 days when the platelet count undergoing autologous transplant received GM-CSF (5 11 (27) 6 ( 
Results

Autologous transplants
This report describes the clinical characteristics, PFS and Autologous transplant recipients were transfused when the OS of 64 patients who underwent BMT or PBPCT at the hemoglobin was less than 80 g/l and platelets less than Toronto and Princess Margaret Hospitals. There was one 10 ϫ 10 12 /l. Ciprofloxacin was administered as antiautologous transplant recipient for whom information about bacterial prophylaxis to the autologous recipients while disease progression was not available. The survival status they were neutropenic. Patients received i.v. cyclophosof all patients was known as of 31 July 1996. phamide (4 g/m 2 ) followed by daily subcutaneous injections of GM-CSF or G-CSF (5-10 g/kg) and PBPC were harvested with two to five daily leukophereses starting Pre-transplant characteristics when the peripheral white blood cell count rose above Forty patients with MM underwent autologous PBPC trans-1 ϫ 10 9 /l. The PBPC harvest was considered adequate plant at the Toronto Hospital between March 1992 and when Ͼ2.5 ϫ 10 6 CD34 cells/kg and Ͼ10 ϫ 10 4 CFUOctober 1995. There were 22 related allogeneic and two GM/kg were collected. Autologous PBPC were cryosyngeneic BM or PBPC transplants performed in patients preserved, stored and thawed as previously described. 18 with MM at the Princess Margaret Hospital between March 1983 and October 1995. Pre-transplant characteristics are shown in Table 1 . Most autologous (29/39, 74%) and alloAllogeneic transplants geneic (16/22, 73%) recipients had chemosensitive disease Between 1983 and 1993, allogeneic transplants were transat transplant. Between 1983 and 1991, patients without fused when the hemoglobin was less than 80 g/l and platechemosensitive disease and those with significant renal lets less than 20 ϫ 10 12 /l. In February 1993, the prophylactic impairment were eligible for allogeneic transplant. Since platelet transfusion threshold was changed and patients were January 1992, chemosensitive disease and adequate renal transfused when the platelet count was less than 10 ϫ 10 12 /l. function (creatinine clearance greater than 60 ml/min) have All allogeneic recipients received trimethoprimbecome prerequisites for consideration of allogeneic transsulfamethoxasole (TMP-SMX) (two tablets p.o. twice a plant. Seven patients underwent allogeneic transplant day) from the start of conditioning until neutrophil before adoption of these criteria. engraftment as anti-bacterial prophylaxis. Thereafter, they
Most pre-transplant characteristics of autologous and received TMP-SMX (two tablets p.o. twice a day for 2 days allogeneic recipients were similar (Table 1 ). The majority a week) as Pneumocystis carinii prophylaxis for at least the of patients had advanced stage disease at diagnosis and first year following transplant and while they remained on transplant (Durie and Salmon stage 2 and 3). Allogeneic immunosuppressive medication. All allogeneic recipients recipients had received a higher median number of chemoreceived total parenteral nutrition from day 1 until they therapy regimens (P Ͻ 0.01) and higher median cycles of were eating adequately. Most (88%) received cyclosporin treatment (P Ͻ 0.01) prior to transplant than the autologous A and methotrexate as GVHD prophylaxis. The remainder recipients, these being the only statistically significant received cyclosporin A, methotrexate or prednisone alone differences between the two groups in pre-transplant or in combination. No harvests were T cell-depleted.
characteristics. Most patients achieved at least a PR Allogeneic PBPC donors received four daily subcutanebefore transplantation. ous injections of G-CSF (5 g/kg) and underwent two leukophereses with a collection of at least 2.5 ϫ 10 6 CD34 Autologous transplants cells/kg recipient weight. Allogeneic BM donors were harvested under general or regional anaesthesia with collection Autologous transplant recipients were usually conditioned of at least 2 ϫ 10 8 mononuclear cells/kg recipient weight. with melphalan, fractionated total body irradiation and etoAll allogeneic donors were related to recipients and poside (29/40) and the majority (32/40) received a regimen matched at HLA-A, HLA-B and HLA-DRB1 loci.
which included radiation. The source of all autologous transplants was PBPC. Neutrophil and platelet engraftment occurred at a median of 11 (7-18) and 11 (6-60) days Statistical analysis respectively and patients were hospitalized for a median of 19 days (11-32) from transplant to first discharge. NeutroPatient characteristics prior to transplant among the autologous and allogeneic transplant groups were compared phil engraftment failure was uncommon (1/36; 3%) but failure of platelet and red cell engraftment occurred in 7 (21%) with the Pearson 2 test if they were represented by a series of categories and the Wilcoxon rank sum test if they were and 9 (27%) of 33 patients at risk who had regular blood counts at our centre. 22 Following transplant, 17/32 (53%) summarized by medians. Two time-to-failure endpoints were analyzed: OS, where death from any cause is conpatients were in CR/N-CR of whom seven had been in CR/N-CR prior to transplant. There were 10/31 (31%) sidered an event, and PFS, where events include disease progression or death from any cause without progression. patients in PR and 5/32 (16%) patients with SD following transplant. Two patients (5%) died within 90 days of OS and PFS plots were produced using the Kaplan-Meier transplant and the eight deaths among autologous recipients were attributed to infection (4), progressive myeloma (2), pulmonary fibrosis (1) and prostatic cancer (1).
Allogeneic transplants
Most allogeneic (14/22) and one syngeneic transplant were conditioned with cyclophosphamide and radiation and 63% (15/24) received radiation ( Table 2 ). The source of most allogeneic and both syngeneic transplants was BM; two allogeneic recipients received PBPC transplants. Neutrophil and platelet engraftment occurred at a median of 18 (13-24) and 18 (13-105) days, respectively, and patients were hospitalized for a median of 33.5 (21-71) days from transplant to first discharge. Failures of neutrophil engraftment (0/19; 0%), platelet engraftment (2/17; 12%) and red cell engraftment (1/17; 6%) were uncommon or not seen.
There were 10 of 16 patients (62%) in CR/N-CR following allogeneic and syngeneic transplant of whom two had been in CR/N-CR prior to transplant. There were 3/16 (19%) in PR and 3/16 (19%) with SD following transplant. Six deaths (27%) occurred within 90 days of transplant and the 16 deaths in the allogeneic patients were attributed to infection (6), progressive myeloma (3), GVHD (1), venoocclusive disease (1), non-infectious pneumonitis (1), toxic epidermal necrolysis (1), renal failure (1), pulmonary hemorrhage (1) and thrombotic thrombocytopenic purpura (1). The incidence of aGVHD was 18/21 (86%) and four of the 21 evaluable patients had stage III/IV aGVHD. One patient died 3 days after transplant of pseudomonal sepsis and was not evaluable for aGVHD. Seven of 15 (47%) patients had cGVHD.
Disease progression and survival
Median follow-up was 14 (1-48) months for all autologous recipients and 15 (6-48) months for those who remain alive. There were 21 progressions and/or deaths in this group of 40 patients. Actuarial PFS and OS are shown in Figures 1a and 2a . Three-year PFS was 17 ± 10% in autologous recipients. Progression occurred in 16 of 39 evaluable recipients at a median of 14 (2-35) months. There Table 2 Conditioning regimens were five progressions among the 17 patients who achieved a CR/N-CR (29%) and 11 progressions among the 22 who did not (50%). There have been eight deaths in the autologous group and among the 32 patients who remain alive, 13 have progressed. Median OS has not yet been reached at the time of writing and is longer than 48 months. Threeyear OS is 74 ± 11%.
Auto Allo Syn
Median follow-up was 7 (0.5-52) months for all allogeneic recipients and 42 (24-52) months for those who remain alive. There were 18 progression and/or deaths in this group of 22 patients. Actuarial PFS and OS are shown in Figures 1b and 2b . Three-year PFS was 22 ± 9% in the allogeneic transplant recipients. There have been five progressions among the 16 patients alive at 90 days posttransplant and these have occurred at a median of 18 months (8-49). Two progressions occurred among those who achieved a CR/N-CR (20%) and three occurred among those who did not (50%). Sixteen of 22 allogeneic recipients have died and among the six who remain alive, two have progressed. Median OS is 7 months and 3-year OS is 32 ± 10%.
Discussion
We report the results of a series of 64 patients with MM treated with autologous (40), allogeneic (22) or syngeneic transplantation (2) at one centre. The pretransplant characteristics of the autologous and allogeneic recipients were similar and most patients in both groups had chemosensitive disease (29/39, auto; 16/22, allo). However, the allogeneic group was more extensively pretreated as assessed by a higher median number of chemotherapy regimens and higher median cycles of therapy prior to transplant. Since treatment assignment was not random, there may have been other differences in prognostic factors between the two groups, limiting their comparability.
Despite this limitation, our study provides an estimate of early (90-day) mortality, PFS and OS of patients undergoing transplantation for MM at one centre. We confirm that autologous transplantation is associated with a low treatment-related mortality and short duration of life-threatening cytopenias and hospitalization, although a subset of our patients remained thrombocytopenic and red cell transfusion dependent for some time. The 90-day mortality of 5% reported here is in the lower range of early mortality rates described in the literature for autologous transplantation in MM. Attal et al 9 described an early mortality of 2.7% in the high-dose therapy arm of their randomized trial where transplantation was undertaken as first-line therapy. Similarly, Cunningham et al 7 reported only one (1.8%) death among 53 patients undergoing autologous transplantation as first-line therapy. Fermand et al, 23 Jagannath et al 11 and Bensinger et al 24 described 90-day mortalities of 11, 11 and 25% in more heavily pretreated patients. transplantation was common in our series with 3-year PFS of 17 ± 10%. However, median OS was greater than 48 months and 3-year OS was 74 ± 11% despite disease pro-gression in the majority of patients. This retrospective References observation suggests that high-dose therapy with hematopo- all patients from our centre, including those transplanted The recently reported randomized trial 9 comparing auto-
